--Poster presentation proposes targeting PPARG for the treatment of muscle-invasive urothelial cancer (MIUC) may help overcome resistance to immunotherapy--

FX-909 is a first-in-class small molecule inhibitor of the PPARG transcription factor for the potential treatment of advanced urothelial carcinoma

Michael L. Meyers, M.D., Ph.D. to join as Chief Medical Officer; Daphne Karydas promoted to President and Chief Financial Officer; Michaela Bowden, Ph.D., promoted to Chief Development Officer; and Jigar Raythatha joins the Board of Directors

Led by GordonMD® Global Investments LP and Pfizer Ventures, financing to support advancement of FX-909, a first-in-class PPARG inhibitor, into the clinic in 2023, along with continued development of Flare’s platform and pipeline of novel transcription factor targets in oncology

Robert Sims, Ph.D., Chief Scientific Officer and co-founder of Flare Therapeutics, will present the discovery of its clinical candidate, FX-909, at the AACR Annual Meeting in Orlando, FL

Robert Sims, Ph.D., Chief Scientific Officer and co-founder at Flare Therapeutics, will present a company overview at the upcoming Guggenheim Healthcare Talks Oncology Day in New York, NY

Daphne Karydas, Chief Operating Officer and Chief Financial Officer of Flare Therapeutics, will present a company overview at the Piper Sandler 34th Annual Healthcare Conference being held in New York, NY

Molecular Real-World Data (RWD) from 3,000+ individuals with advanced and metastatic urothelial cancer highlight Peroxisome Proliferator-Activated Receptor Gamma (PPARG) as a lineage defining transcription factor is foundational to Flare’s precision oncology approach

Data highlight the potential for novel small molecule inhibitors of key transcription factors to target and effectively treat advanced UC

Biopharma industry veteran to lead advancement of company’s transcription factor-focused pipeline into clinical stage and expand discovery efforts

Dr. Jubb’s research and clinical development experience strongly positions company for clinical excellence in advancing precision oncology pipeline

Company expands leadership team across business and science as it advances precision oncology pipeline

Company has pioneered ‘switch site’ approach to uncover druggable regions within well validated, but elusive, transcription factors that are master regulators of gene expression